On January 16, 2025, GT Medical Technologies, Inc. (GT MedTech), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, announced that it has completed a $37 million first close of a Series D financing round. The financing was led by Evidity Health Capital, alongside new investor Accelmed Partners. Also participating were existing investors MVM Partners, Gilde Healthcare, and Medtech Venture Partners. Wilson Sonsini Goodrich & Rosati advised Evidity Health Capital on IP matters related to the transaction.

The funds will accelerate the completion of the ROADS clinical study that is focused on GammaTile for newly diagnosed brain metastases, and the GESTALT clinical trial for patients with newly diagnosed glioblastomas (GBMs). In addition, the funds will support the continued commercialization of GammaTile®, GT MedTech’s FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors.

The Wilson Sonsini team that advised Evidity Health Capital on IP matters included Bill Barrett, Darby Chan, Karl Hudspith, Tess Oram, and Sarah Ko.

For more information, please see the news release.